Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131830) titled 'REcaticimab for Vascular Efficacy in ReverSing coronary athErosclerotic Plaques: A Multicenter, Prospective, Open-Label, Pragmatic Randomized Controlled Trial(REVERSE)' on Sept. 7.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition:
Cardiovascular disease
Intervention:
Experimental Group: Original treatment + Recaticimab 300mg, Q8W
(Note: Original treatment refers to maintaining the patient's existing treatment regimen without modification)
Control Group: Basic lipid-lowering treatment
Recruitment Stat...